Stock Research: Kalbe Farma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Kalbe Farma

IDX:KLBF ID1000125107
100
  • Value
    92
  • Growth
    37
  • Safety
    Safety
    87
  • Combined
    100
  • Sentiment
    92
  • 360° View
    360° View
    100
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

PT Kalbe Farma Tbk is an Indonesian company engaged in developing, manufacturing, and trading pharmaceutical products. It operates in the pharmaceutical, consumer health, nutritional, and distribution industries. The company primarily operates in Indonesia. In the last fiscal year, the company had a market cap of $4,349 million, profits of $778 million, and revenue of $2,028 million, with 12,903 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 100 (better than 100% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Kalbe Farma are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Kalbe Farma. The consolidated Value Rank has an attractive rank of 87, which means that the share price of Kalbe Farma is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 87% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 92. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 92. But the consolidated Growth Rank has a low rank of 37, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 63 of its competitors have better growth. ...read more

more
Index
IDX Composite
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 4-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
87 77 69 69
Growth
37 17 17 45
Safety
Safety
92 79 79 81
Sentiment
92 99 63 79
360° View
360° View
100 89 65 95
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
89 76 38 69
Opinions Change
44 56 50 50
Pro Holdings
n/a 100 35 16
Market Pulse
77 100 95 95
Sentiment
92 99 63 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
87 77 69 69
Growth
37 17 17 45
Safety Safety
92 79 79 81
Combined
100 75 61 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
78 70 58 48
Price vs. Earnings (P/E)
75 73 69 65
Price vs. Book (P/B)
64 66 59 55
Dividend Yield
88 77 74 68
Value
87 77 69 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
32 25 23 27
Profit Growth
48 57 26 45
Capital Growth
59 20 92 85
Stock Returns
19 29 9 37
Growth
37 17 17 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
77 74 62 70
Refinancing
82 80 74 78
Liquidity
68 50 72 61
Safety Safety
92 79 79 81

Similar Stocks

Discover high‑ranked alternatives to Kalbe Farma and broaden your portfolio horizons.

Vodacom

JSE:VOD
Country: South Africa
Industry: Wireless Telecommunication
Size: X-Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Perusahaan Gas

IDX:PGAS
Country: Indonesia
Industry: Gas Utilities
Size: Medium
Full Stock Analysis

Ambev

BOVESPA:ABEV3
Country: Brazil
Industry: Brewers
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.